Auris – executive interview

Auris – executive interview

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase II) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase Ib). With AM-301, Auris is developing a nasal spray for protection against airborne pathogens and allergens.

In this video, Auris founder and chief executive officer Thomas Meyer provides an update on the company’s lead programs, AM-125 and AM-201, discussing recently received positive data and outlining key milestones for Q4 and 2021. Thomas also introduces the company’s new program, AM-301, and discusses the how the establishment of its new subsidiary, Altamira Medica, will support this ongoing development.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.